FDA: Many post-market studies have not begun

04/24/2008 | Bloomberg1

A federal report found that drugmakers, as of Sept. 30, had not begun 1,044 post-market drug studies that they agreed to perform. An industry official said studies can be delayed because of conversations with the agency over their design, as well as difficulty recruiting patients. An FDA spokeswoman said the agency will make sure drug firms finish the incomplete post-approval trials "in a timely manner."

View Full Article in:

Bloomberg1

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC